Jianan Huang

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4.1K citations

Medicine, Oncology, Pharmacology +10

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

Nan Zhang, Yuanyuan Zeng, Wenwen Du et al. · International Journal of Oncology · 2016 · 384 citations

Life Sciences, Immunology, Oncology +14

Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis

Jingyu Chen, Kun Qiao, Feng Liu et al. · Chinese Medical Journal · 2020 · 188 citations · Full text

Medicine, Infectious Diseases, Surgery +12

Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation

Shenjie Tang, Shouyong Tan, Lan Yao et al. · PLoS ONE · 2013 · 128 citations · Full text

Public Health, Infectious Diseases, Internal Medicine +16

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 120 citations · Full text

Medicine, Oncology, Pharmacology +14